Literature DB >> 36214960

Design, synthesis, and pharmacological evaluation of [1, 3] dioxolo-chromeno[2,3-b]pyridines as anti-seizure agents.

Visarapu Malathi1, Nissi Sharon1, Pannala Padmaja2, Deepak Lokwani3, Saurabh Khadse4, Prashant Chaudhari4, Atul A Shirkhedkar4, Pedavenkatagari Narayana Reddy5, Vinod G Ugale6,7.   

Abstract

An efficient one-pot three-component reaction for the synthesis of [1,3]dioxolo[4',5':6,7]chromeno[2,3-b]pyridines 4(a-i) has been developed. Synthesis was achieved by reacting sesamol (1), aromatic aldehydes 2(a-i), and 2-aminopropene-1,1,3-tricarbonitrile (3) in the presence of triethylamine at 100 °C under neat reaction condition. Simple operational procedure, broad substrate scope, column chromatography free separations, and high yield of products make it an efficient and largely acceptable synthetic strategy. Synthesized compounds 4(a-i) were further screened for preliminary anticonvulsant activity using MES and scPTZ tests. These analogs were also checked for neurotoxicity and hepatotoxicity. Selected active compounds have been then screened quantitatively to determine ED50 and TD50 values. Analog 4h was found effective in both preclinical seizure models with significant therapeutic/toxicity profile (4h: ED50 = 34.7 mg/kg, MES test; ED50 = 37.9 mg/kg, scPTZ test; TD50 = 308.7 mg/kg). Molecular dynamic simulation for 100 ns of compound 4h-complexed with GABAA receptor revealed good thermodynamic behavior and fairly stable interactions (4h, Docking score =  - 10.94). In conclusion, effective synthetic strategy, significant anticonvulsant activity with good toxicity profile and detailed molecular modeling studies led us to anticipate the emergence of these analogs as valid leads for the development of future effective neurotherapeutic agents.
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Keywords:  Anticonvulsants; Design; Molecular docking; Synthesis; [1,3]Dioxolochromeno[2,3-b]pyridines

Year:  2022        PMID: 36214960     DOI: 10.1007/s11030-022-10538-x

Source DB:  PubMed          Journal:  Mol Divers        ISSN: 1381-1991            Impact factor:   3.364


  30 in total

Review 1.  Adverse effects of antiepileptic drugs: a brief overview of important issues.

Authors:  Joyce A Cramer; Scott Mintzer; James Wheless; Richard H Mattson
Journal:  Expert Rev Neurother       Date:  2010-06       Impact factor: 4.618

2.  Design, synthesis and antiproliferative activity of some new azapyranoxanthenone aminoderivatives.

Authors:  George Kolokythas; Nicole Pouli; Panagiotis Marakos; Harris Pratsinis; Dimitris Kletsas
Journal:  Eur J Med Chem       Date:  2005-11-21       Impact factor: 6.514

Review 3.  Synthetic and therapeutic perspectives of nitrogen containing heterocycles as anti-convulsants.

Authors:  Gourav Grover; Rajarshi Nath; Rohit Bhatia; Md Jawaid Akhtar
Journal:  Bioorg Med Chem       Date:  2020-06-13       Impact factor: 3.641

4.  NAD+-dependent DNA Ligase (Rv3014c) from Mycobacterium tuberculosis. Crystal structure of the adenylation domain and identification of novel inhibitors.

Authors:  Sandeep Kumar Srivastava; Rama Pati Tripathi; Ravishankar Ramachandran
Journal:  J Biol Chem       Date:  2005-05-17       Impact factor: 5.157

Review 5.  The safety and tolerability of newer antiepileptic drugs in children and adolescents.

Authors:  Dean P Sarco; Blaise F D Bourgeois
Journal:  CNS Drugs       Date:  2010-05       Impact factor: 5.749

Review 6.  Reactive metabolites of the anticonvulsant drugs and approaches to minimize the adverse drug reaction.

Authors:  Rohit Pal; Karanvir Singh; Shah Alam Khan; Pooja Chawla; Bhupinder Kumar; Md Jawaid Akhtar
Journal:  Eur J Med Chem       Date:  2021-10-02       Impact factor: 6.514

Review 7.  Quinazolines: new horizons in anticonvulsant therapy.

Authors:  Vinod G Ugale; Sanjay B Bari
Journal:  Eur J Med Chem       Date:  2014-04-28       Impact factor: 6.514

8.  Specific and potent inhibition of NAD+-dependent DNA ligase by pyridochromanones.

Authors:  Heike Brötz-Oesterhelt; Igor Knezevic; Stephan Bartel; Thomas Lampe; Ute Warnecke-Eberz; Karl Ziegelbauer; Dieter Häbich; Harald Labischinski
Journal:  J Biol Chem       Date:  2003-07-15       Impact factor: 5.157

Review 9.  CNS adverse events associated with antiepileptic drugs.

Authors:  Gina M Kennedy; Samden D Lhatoo
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

10.  Cancer chemopreventive effect of phenothiazines and related tri-heterocyclic analogues in the 12-O-tetradecanoylphorbol-13-acetate promoted Epstein-Barr virus early antigen activation and the mouse skin two-stage carcinogenesis models.

Authors:  Magnus A Azuine; Harukuni Tokuda; Junko Takayasu; Fumio Enjyo; Teruo Mukainaka; Takao Konoshima; Hoyoku Nishino; Govind J Kapadia
Journal:  Pharmacol Res       Date:  2004-02       Impact factor: 7.658

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.